No relevant news for DaVita Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 Jan 26
Source: Fool
DaVita Inc's stock price fell significantly, hitting a 52-week low during regular trading.
The decline in DaVita's stock is attributed to broad market weakness, as both the Nasdaq-100 and S&P 500 are down by 0.29% and 0.28%, respectively. This market trend has influenced investor sentiment negatively, leading to a sell-off in various stocks, including DaVita.
Investors are closely monitoring the overall market conditions, which may continue to impact DaVita's stock performance in the near term.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 136.50 USD with a low forecast of 130.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
0 Buy
3 Hold
1 Sell
Hold
Current: 105.880
Low
130.00
Averages
136.50
High
143.00
Current: 105.880
Low
130.00
Averages
136.50
High
143.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





